Business Standard

Jubilant Pharmova Q4 results: Consolidated net loss narrows to Rs 5.86 cr

Revenue from segments that make copycat drugs and medicines used for allergy immunotherapy rose 0.8% and 14%, respectively, during the quarter

Q4, Q4 results

Photo: Shutterstock

Reuters

Listen to This Article

Indian pharmaceutical firm Jubilant Pharmova reported a narrower fourth-quarter loss on Wednesday, aided by strong demand for drugs that contain radioactive ingredients.
 
The company's consolidated net loss narrowed to Rs 5.86 crore ($7 million) in the January to March period, compared with a loss of Rs 9.79 crore a year ago.
 
Jubilant Pharmova, involved in the manufacturing and supply of radiopharmaceuticals with a network of 46 radio-pharmacies in the U.S., said it is on track to launch new products in this segment in the medium-term.

Sales rose 5% to Rs 1,746 crore in the fourth quarter, lifted by an 18.6% rise in the key radiopharma business, which involves developing medications used to diagnose or treat diseases such as cancer, and made up nearly half of the sales.
 
Revenue from segments that make copycat drugs and medicines used for allergy immunotherapy rose 0.8% and 14%, respectively, during the quarter.
 
The drugmaking arm of the polymers-to-pizza Jubilant Bhartia group declared a dividend of 5 rupees per share.
Its shares ended 0.4% higher after results and are up 29.5% so far this year.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 29 2024 | 4:12 PM IST

Explore News